GMPriority Pharma

GMPriority Pharma wins
Pharmaceutical Company of the Year

The accolade was accepted at the Corporate Livewire Awards in Surrey in the Innovation and Excellence category, 2023.

Surrey – 06/09/2023

GMPriority Pharma are delighted to have received the prestigious Corporate Livewire Award for Pharmaceutical Company of the Year (2023) in the Innovation and Excellence category.

The team, based in Coggeshall, Essex, picked up the top prize for their continuous innovation, development and manufacture of liposomal formulas for scientific and technical application.

Chief Scientist Professor Mohammad Najlah, Professor of Pharmaceutics & Nanomedicine and Pharmaceutical Research Group Lead at Anglia Ruskin University, pioneered the build of a new, state-of-the-art manufacturing facility, incorporating R&D laboratories, Class 7 cleanroom, and accredited FSSC ISO 22000 production suite.  The premises was purposefully designed to develop cutting edge liposomal technologies in both liquid and dry forms for commercial, nutraceutical and pharmaceutical applications.

GMPriority Pharma CEO and co-founder Gareth Meyer said:

“This award is recognition of our expertise in the field of liposomal encapsulation. No other liposomal manufacturer has the depth of knowledge we hold at GMPriority Pharma; fusing academia, science, research and development with experience spanning decades. We look forward to continuously pushing the boundaries of nutraceutical products to help deliver a greater quality of life to millions around the world.”

The judging panel was particularly impressed by the diverse success of GMPriority Pharma, in one of the most dynamic sectors of the nutraceutical industry.

Since being awarded a highly-contested KTP grant by Innovate UK in 2020, GMPriority Pharma have developed their lipolife brand of liposomal products further than they could have ever imagined. Formulations, homogenisation and encapsulation potential are at a market leading standard.

The first ever commercial liposomal manufacturer in Europe, GMPriority Pharma also has formulae involved in ongoing, groundbreaking clinical trials against cancer cell lines which have already seen notable success. The applications of the work taking place are myriad – from life-enhancing nutraceuticals to market-leading skincare and cosmetic products, GMPriority Pharma is already playing a significant part in the future of scientific research in this field.